295.48
+3.5515(+1.22%)
Currency In USD
| Previous Close | 291.93 |
| Open | 292.4 |
| Day High | 295.98 |
| Day Low | 287.57 |
| 52-Week High | 295.98 |
| 52-Week Low | 122.8 |
| Volume | 189,257 |
| Average Volume | 307,420 |
| Market Cap | 8.57B |
| PE | 44.3 |
| EPS | 6.67 |
| Moving Average 50 Days | 228.45 |
| Moving Average 200 Days | 172.91 |
| Change | 3.55 |
If you invested $1000 in Krystal Biotech, Inc. (KRYS) since IPO date, it would be worth $27,770.82 as of January 14, 2026 at a share price of $295.482. Whereas If you bought $1000 worth of Krystal Biotech, Inc. (KRYS) shares 5 years ago, it would be worth $4,454.05 as of January 14, 2026 at a share price of $295.482.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 11, 2026 6:00 PM GMT
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, In
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
GlobeNewswire Inc.
Jan 08, 2026 9:01 PM GMT
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
Investor call to be held January 8 at 4:30 pm ET to discuss data update and next stepsPITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call a